We are pleased to have completed the NHS Evergreen Sustainable Supplier Assessment. The Assessment, which is self-assessment and reporting tool, resulted in us receiving a Level 2: Comprehensive net zero targets and reporting for carbon emissions. The information reported through Evergreen is supporting us to understand our alignment with NHS…

Mawdsleys and Oncoscience GMbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingdom (UK) and Ireland to obtain access to CIMAher® (Nimotuzumab) on an unlicensed basis for the treatment of various types of cancer.   Nimotuzumab has been approved for marketing in 25 different countries worldwide for a variety of…